Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Other solid neoplasm 1

Conditions

Neoplasms 2Solid Tumor 1Neoplasm Metastasis 1

Interventions

pembrolizumab 110Paclitaxel 65Cyclophosphamide 65Cisplatin 60Carboplatin 56Gemcitabine 48Radiotherapy 45Nivolumab 44fludarabine 38Docetaxel 38Pemetrexed 33Dexamethasone 32Capecitabine 32Lenalidomide 26fludarabine phosphate 25Rituximab 25Radiation 25Ipilimumab 25Doxorubicin 25Irinotecan 24Bevacizumab 24Azacitidine 24Vorinostat 23Vincristine 22Cytarabine 22Temozolomide 20Etoposide 20Oxaliplatin 19Fluorouracil 19atezolizumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Has results × LY3022855 × Clear all
NCT02265536 2024-10-28

A Study of LY3022855 In Participants With Breast or Prostate Cancer

Eli Lilly and Company

Phase 1 Completed
34 enrolled 17 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01346358 2024-09-19

A Study of IMC-CS4 in Subjects With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
52 enrolled 23 charts
Tumor-Agnostic

Neoplasms

NCT02718911 2023-10-16

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
72 enrolled 23 charts
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡